Mode
Text Size
Log in / Sign up
N/A N=80

Assessment of the Capability of PulmoVista 500 to Continuously Monitor Changes of Ventilation Over Time

Mechanical Ventilation · Single-lung Ventilation · ARDS · ALI - Acute Lung Injury · Weaning From Ventilator

Enrolled (actual)
80
Serious AEs
10.0%
Results posted
Oct 2019
Primary outcome: Primary: Monitoring Capabilities of PulmoVista 500 — 0.9692; 0.9093 correlation coefficient

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Lung Monitoring with EIT device (PulmoVista 500) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Drägerwerk AG & Co. KGaA
Primary completion
Apr 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Monitoring Capabilities of PulmoVista 500
0.9692; 0.9093
SECONDARY
Detection of Changes in Regional Ventilation
0.9093
SECONDARY
Assess Changes of Tidal Volumes
3; 49; 3
SECONDARY
Assess Changes of the End-expiratory Lung Volumes
1; 51; 3; 0; 29; 26
SECONDARY
Safety - Documentation of Any Safety Events
43; 13; 12; 12; 55; 25
SECONDARY
Assessing the Use Specific Clinical Helpfulness of PulmoVista 500 by Particular Questionnaire. The Questions Which Were Asked Within the Questionaire Are Listed in the "Outcome Measure Description"
0; 0; 0; 0; 2; 0

Summary

The results of this study will help to define the capability and reliability of PulmoVista 500 to detect changes in both global and regional ventilation.

Eligibility Criteria

Inclusion Criteria

  • The population included in the clinical study will be selected from a pool of patients undergoing respiratory support who are scheduled to have their ventilation settings changed.

As a subgroup, patients who are scheduled for surgeries that need one-lung-ventilation (OLV) will be enrolled to the study.

  • Male and female patients at the age of 18 years or older
  • On respiratory support in ICU care or scheduled for such ( e.g. postoperatively) or scheduled for surgery with OLV
  • Patients of which the monitoring of ventilation distribution may be of clinical interest
  • Patients being ventilated via an artificial airway with a mechanical ventilator that is compatible with PulmoVista 500
  • Patients scheduled for changes in ventilation settings that may cause relevant changes in the ventilation
  • Chest circumference between 70 and 150 cm
  • Written informed consent to participate in the study provided by either the patient or the legal representative of the patient.

Exclusion Criteria

  • Currently has a permanent or temporary pacemaker, implantable cardiac device (ICD) or other device emitting electrical energy
  • a BMI ≥ 50
  • tidal volume (VT) ≤ 200 mL
  • Current uncontrolled body movements such as tics, tremors or seizures,
  • Current wound dressings or infections on the chest that might interfere with the PulmoVista 500 electrode belt placement
  • Women of child bearing potential whose pregnancy cannot be excluded based on a pregnancy test or other proven facts.
  • Allergic to materials used in the electrode belt
  • Participation of the patient in an interventional trial within the last four weeks before enrollment in this trial
  • Evidence suggesting that the patient or his legal representative is not likely to follow the trial protocol (e.g. lacking compliance)
  • Known infectious diseases that require isolation of patient (e.g. MRSA)
  • Concomitant use of an air anti-decubitus medical mattress with dynamic inflation that cannot be deactivated during EIT measurements
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03076983). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search